Showing results 1 to 2 of 2
| Issue Year | Title | Author(s) | Type | Views | Downloads |
|---|---|---|---|---|---|
| 2023 | KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC | Ren, S.; Feng, J.; Ma, S.; Chen, H.; Ma, Z.; Huang, C.; Zhang, L.; He, J.; Wang, C.; Zhou, J.; Danchaivijitr, P.; Wang, C.-C.; Vynnychenko, Ihor Oleksandrovych; Wang, K.; Orlandi, F.; Sriuranpong, V.; Li, B.; Ge, J.; Dang, T.; Zhou, C. | Article | 726 | 796 |
| 2021 | Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study | Gafanov, R.; Powles, T.B.; Bedke, J.; Stus, V.; Waddell, T.S.; Nosov, D.; Pouliot, F.; Soulieres, D.; Melichar, B.; Azevedo, S.; McDermott, R.S.; Vynnychenko, Ihor Oleksandrovych; Borchiellini, D.; Markus, M.; Bondarenko, I.; Lin, J.; Burgents, J.; Molife, L.R.; Plimack, E.R.; Rini, B. | Conference Papers | 13882134 | 3196872 |